{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:14:44Z","timestamp":1791630884670,"version":"4.3.4"},"reference-count":228,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT94252310175"],"award-info":[{"award-number":["HT94252310175"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT94252310223"],"award-info":[{"award-number":["HT94252310223"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","award":["CRDG-2024-3-1550"],"award-info":[{"award-number":["CRDG-2024-3-1550"]}],"id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02438-z","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:14:40Z","timestamp":1760447680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics"],"prefix":"10.1186","volume":"24","author":[{"given":"Samrita","family":"Dogra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Burgett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dockery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajani","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitha Redempta","family":"Isingizwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany N.","family":"Hannafon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"1","key":"2438_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"2438_CR2","unstructured":"Surveillance E, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 8 Registries, Nov 2023 Sub (1975\u20132021) - Linked To County Attributes - Time Dependent (1990\u20132022) Income\/Rurality, 1969\u20132022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission."},{"issue":"4","key":"2438_CR3","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"2438_CR4","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"2438_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"issue":"25","key":"2438_CR6","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"2438_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681\u201392.","journal-title":"Ann Oncol"},{"issue":"26","key":"2438_CR8","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"25","key":"2438_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"3 Pt 1","key":"2438_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","volume":"108","author":"JK Chan","year":"2006","unstructured":"Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108(3 Pt 1):521\u20138.","journal-title":"Obstet Gynecol"},{"key":"2438_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116215","author":"M Rakina","year":"2022","unstructured":"Rakina M, Kazakova A, Villert A, Kolomiets L, Larionova I. Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components Spheroid formation and peritoneal metastasis in ovarian cancer: the role of stromal and immune components. Int J Mol Sci. Jun 1; 2022. PMID: 35682890; PMCID:PMC9181487 https:\/\/doi.org\/10.3390\/ijms23116215","journal-title":"Int J Mol Sci"},{"key":"2438_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174318","author":"BP Rickard","year":"2021","unstructured":"Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, Franco W, Scarcelli G,Polacheck WJ, Roque DM, Del Carmen MG, Huang HC, Demirci U, Rizvi I.. Malignant Ascites inOvarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristicsand Therapy Response.Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel). 13(17):4318. 2021 Aug 26. PMID: 34503128; PMCID: PMC8430600 https:\/\/doi.org\/10.3390\/cancers13174318","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2438_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.21037\/apm-23-554","volume":"13","author":"T Ikegami","year":"2024","unstructured":"Ikegami T, Ishiki H, Kadono T, Ito T, Yokomichi N. Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment. Ann Palliat Med. 2024;13(4):842\u201357.","journal-title":"Ann Palliat Med"},{"issue":"1","key":"2438_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084941","volume":"9","author":"J Liao","year":"2014","unstructured":"Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, et al. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One. 2014;9(1):e84941.","journal-title":"PLoS One"},{"issue":"1","key":"2438_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93718-3","volume":"11","author":"M Yoshihara","year":"2021","unstructured":"Yoshihara M, Emoto R, Kitami K, Iyoshi S, Uno K, Mogi K, et al. A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer. Sci Rep. 2021;11(1):15154.","journal-title":"Sci Rep"},{"issue":"1","key":"2438_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-025-01657-8","volume":"18","author":"LH Chow","year":"2025","unstructured":"Chow LH, Ngai AMY, Tang CY, Lee JHS, Lee ALH, Li JJX, et al. Malignant ascites in ovarian cancer is compatible with long-term (10 year) survival with associations to clinicopathological features. J Ovarian Res. 2025;18(1):98.","journal-title":"J Ovarian Res"},{"issue":"3","key":"2438_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/dc.20200","volume":"32","author":"LR Ylagan","year":"2005","unstructured":"Ylagan LR, Zhai J. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Diagn Cytopathol. 2005;32(3):137\u201344.","journal-title":"Diagn Cytopathol"},{"issue":"6","key":"2438_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1159\/000326453","volume":"48","author":"C Gabriel","year":"2004","unstructured":"Gabriel C, Achten R, Drijkoningen M. Use of liquid-based cytology in serous fluids: a comparison with conventional cytopreparatory techniques. Acta Cytol. 2004;48(6):825\u201335.","journal-title":"Acta Cytol"},{"issue":"Suppl 1","key":"2438_CR19","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","volume":"9","author":"DB Chapel","year":"2020","unstructured":"Chapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S3-27.","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"2438_CR20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/00000478-199810000-00005","volume":"22","author":"NG Ordonez","year":"1998","unstructured":"Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22(10):1203\u201314.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2438_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.pap.0000201832.15591.1d","volume":"13","author":"NG Ordonez","year":"2006","unstructured":"Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13(1):16\u201325.","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"2438_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ajcp\/aqaa028","volume":"154","author":"A Bansal","year":"2020","unstructured":"Bansal A, Srinivasan R, Rohilla M, Sundaram A, Rai B, Rajwanshi A, et al. Morphologic and immunocytochemical features of high-grade serous carcinoma of ovary in ascitic fluid effusion and fine-needle aspiration cytology. Am J Clin Pathol. 2020;154(1):103\u201314.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2438_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/dc.24734","volume":"49","author":"H Iwahashi","year":"2021","unstructured":"Iwahashi H, Miyamoto M, Minabe S, Hada T, Sakamoto T, Ishibashi H, et al. Diagnostic efficacy of ascites cell block for ovarian clear cell carcinoma. Diagn Cytopathol. 2021;49(6):735\u201342.","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"2438_CR24","first-page":"236","volume":"64","author":"R Zivadinovic","year":"2015","unstructured":"Zivadinovic R, Petric A, Krtinic D, Milosevic JS, Dinic S Pop Trajkovic. Ascites in ovarian carcinoma - reliability and limitations of cytological analysis. West Indian Med J. 2015;64(3):236\u201340s.","journal-title":"West Indian Med J."},{"issue":"1","key":"2438_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-025-01653-y","volume":"18","author":"B Thibault","year":"2025","unstructured":"Thibault B, D\u2019Angelo R, Rigal S, White-Koning M, Bataillon G, Guillermet-Guibert J, et al. Morphometric analysis of neoplastic cell clusters in high-grade serous ovarian cancer ascites identifies a promising prognostic factor: a retrospective study. J Ovarian Res. 2025;18(1):74.","journal-title":"J Ovarian Res"},{"key":"2438_CR26","doi-asserted-by":"publisher","unstructured":"Iyoshi S, Sunohara M, Yoshihara M, Kunishima A, Miyamoto E, Fujimoto H, Kitami K, MogiK, Uno K, Yoshida K, Tamauchi S, Yokoi A, Niimi K, Yoshikawa N, Emoto R, Matsui S, Kajiyama H. Long-term prognostic significance of ascites cytology in ovarian cancer cases in which R0 resection was achieved in the initial surgery: a multi-institutional retrospective cohort study. JpnJ Clin Oncol. 2025 Jul 6 ; 55(7):743-750. https:\/\/doi.org\/10.1093\/jjco\/hyaf046.","DOI":"10.1093\/jjco\/hyaf046"},{"key":"2438_CR27","doi-asserted-by":"publisher","unstructured":"Lee J, Choi S, Shin S, Alam MR, Abdul-Ghafar J, Seo KJ,\u00a0Hwang G, Jeong D, Gong G, Cho NH, Yoo CW, Kim HK, Chong Y, Yim K.\u00a0Ovarian Cancer Detection in Ascites Cytology with WeaklySupervised Model on Nationwide Data Set.. Am J Pathol. 2025\u00a0Jul;195(7):1254-1263. https:\/\/doi.org\/10.1016\/j.ajpath.2025.04.004.\u00a0Epub 2025 Apr 30. PMID: 40311756","DOI":"10.1016\/j.ajpath.2025.04.004"},{"issue":"3","key":"2438_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4143\/crt.2019.700","volume":"52","author":"MR Han","year":"2020","unstructured":"Han MR, Lee SH, Park JY, Hong H, Ho JY, Hur SY, et al. Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer. Cancer Res Treat. 2020;52(3):779\u201388.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"2438_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ygyno.2021.06.028","volume":"162","author":"B Werner","year":"2021","unstructured":"Werner B, Yuwono N, Duggan J, Liu D, David C, Srirangan S, et al. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecol Oncol. 2021;162(3):720\u20137.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"2438_CR30","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1002\/1878-0261.13710","volume":"18","author":"B Werner","year":"2024","unstructured":"Werner B, Powell E, Duggan J, Cortesi M, Lee YC, Arora V, et al. Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer. Mol Oncol. 2024;18(11):2668\u201383.","journal-title":"Mol Oncol"},{"issue":"1","key":"2438_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01864-1","volume":"22","author":"C Roussel-Simonin","year":"2023","unstructured":"Roussel-Simonin C, Blanc-Durand F, Tang R, Vasseur D, Le Formal A, Chardin L, et al. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid. Mol Cancer. 2023;22(1):178.","journal-title":"Mol Cancer"},{"key":"2438_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1537407","volume":"12","author":"I Kurelac","year":"2025","unstructured":"Kurelac I, Sollazzo M, De Luise M, Nanetti F, Lanteri L, D\u2019Angelo L, et al. Immunomagnetic enrichment coupled to PAX8\/TP53 molecular pathology approach increases sensitivity in the detection of ovarian cancer cells in ascites. Front Mol Biosci. 2025;12:1537407.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2438_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"2438_CR34","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/ijc.24886","volume":"126","author":"M Pasquet","year":"2010","unstructured":"Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer. 2010;126(9):2090\u2013101.","journal-title":"Int J Cancer"},{"issue":"8","key":"2438_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10585-016-9821-y","volume":"33","author":"I Matte","year":"2016","unstructured":"Matte I, Legault CM, Garde-Granger P, Laplante C, Bessette P, Rancourt C, et al. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clin Exp Metastasis. 2016;33(8):839\u201352.","journal-title":"Clin Exp Metastasis"},{"issue":"37","key":"2438_CR36","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41388-018-0317-x","volume":"37","author":"S Al Habyan","year":"2018","unstructured":"Al Habyan S, Kalos C, Szymborski J, McCaffrey L. Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer. Oncogene. 2018;37(37):5127\u201335.","journal-title":"Oncogene"},{"issue":"15","key":"2438_CR37","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-07-0307","volume":"67","author":"M Satpathy","year":"2007","unstructured":"Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, et al. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res. 2007;67(15):7194\u2013202.","journal-title":"Cancer Res"},{"key":"2438_CR38","doi-asserted-by":"publisher","unstructured":"Capellero S, Erriquez J, Battistini C, Porporato R, Scotto G, Borella F,\u00a0Di Renzo MF, Valabrega G, Olivero M. Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. Int J Mol Sci. 2022 Jan 13;23(2):833. https:\/\/doi.org\/10.3390\/ijms23020833.\u00a0PMID: 35055018; PMCID:PMC8775835.","DOI":"10.3390\/ijms23020833"},{"issue":"1","key":"2438_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/1878-0261.13556","volume":"18","author":"N Gendrau-Sanclemente","year":"2024","unstructured":"Gendrau-Sanclemente N, Figueras A, Gracova K, Lahiguera A, Alsina-Sanchis E, Marin-Jimenez JA, et al. Ovarian cancer relies on the PDGFRbeta-fibronectin axis for tumorsphere formation and metastatic spread. Mol Oncol. 2024;18(1):136\u201355.","journal-title":"Mol Oncol"},{"key":"2438_CR40","doi-asserted-by":"publisher","unstructured":"Boylan KLM, Walz C, Schefter AM, Skubitz APN.\u00a0A Peptide Derived from Nectin-4 IncreasesCisplatin Cytotoxicity in Cell Lines and Cells from Ovarian Cancer Patients' Ascites. Cancers (Basel). 2025\u00a0Mar 6;17(5):901. https:\/\/doi.org\/10.3390\/cancers17050901.\u00a0PMID: 40075748; PMCID:PMC11899234.","DOI":"10.3390\/cancers17050901"},{"issue":"2","key":"2438_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2012.01.030","volume":"321","author":"X Yang","year":"2012","unstructured":"Yang X, Wang J, Zhou Y, Wang Y, Wang S, Zhang W. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett. 2012;321(2):137\u201343.","journal-title":"Cancer Lett"},{"key":"2438_CR42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"issue":"7","key":"2438_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131579","volume":"10","author":"L Mo","year":"2015","unstructured":"Mo L, Pospichalova V, Huang Z, Murphy SK, Payne S, Wang F, et al. Ascites increases expression\/function of multidrug resistance proteins in ovarian cancer cells. PLoS One. 2015;10(7):e0131579.","journal-title":"PLoS One"},{"issue":"7","key":"2438_CR44","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/j.1349-7006.2007.00492.x","volume":"98","author":"Y Oda","year":"2007","unstructured":"Oda Y, Ohishi Y, Basaki Y, Kobayashi H, Hirakawa T, Wake N, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP\/MVP and P-glycoprotein expression. Cancer Sci. 2007;98(7):1020\u20136.","journal-title":"Cancer Sci"},{"issue":"9","key":"2438_CR45","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1245\/s10434-013-2878-9","volume":"20","author":"EH Kerr","year":"2013","unstructured":"Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, et al. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. Ann Surg Oncol. 2013;20(9):3059\u201365.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2438_CR46","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/sj.bjc.6605626","volume":"102","author":"L Hu","year":"2010","unstructured":"Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010;102(8):1276\u201383.","journal-title":"Br J Cancer"},{"issue":"3","key":"2438_CR47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1158\/1535-7163.MCT-14-0579","volume":"14","author":"L Mo","year":"2015","unstructured":"Mo L, Bachelder RE, Kennedy M, Chen PH, Chi JT, Berchuck A, et al. Syngeneic murine ovarian cancer model reveals that ascites enriches for ovarian cancer stem-like cells expressing membrane GRP78. Mol Cancer Ther. 2015;14(3):747\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2438_CR48","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1002\/1878-0261.13028","volume":"15","author":"Y Ding","year":"2021","unstructured":"Ding Y, Labitzky V, Legler K, Qi M, Schumacher U, Schmalfeldt B, et al. Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer. Mol Oncol. 2021;15(12):3578\u201395.","journal-title":"Mol Oncol"},{"issue":"1","key":"2438_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-018-0462-4","volume":"11","author":"SB Liu","year":"2018","unstructured":"Liu SB, Lin XP, Xu Y, Shen ZF, Pan WW. DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway. J Ovarian Res. 2018;11(1):90.","journal-title":"J Ovarian Res"},{"issue":"2","key":"2438_CR50","doi-asserted-by":"publisher","first-page":"101283","DOI":"10.1016\/j.gendis.2024.101283","volume":"12","author":"L Wang","year":"2025","unstructured":"Wang L, Luo N, Zhu J, Sulaiman Z, Yang W, Hu K, et al. Peritoneal adipose stem cell-derived extracellular vesicles mediate the regulation of ovarian cancer cell proliferation and migration through EGFR-NF-kappaB signaling. Genes Dis. 2025;12(2):101283.","journal-title":"Genes Dis"},{"issue":"1","key":"2438_CR51","doi-asserted-by":"publisher","first-page":"114155","DOI":"10.1016\/j.yexcr.2024.114155","volume":"441","author":"C Laurent-Issartel","year":"2024","unstructured":"Laurent-Issartel C, Landras A, Agniel R, Giffard F, Blanc-Fournier C, Da Silva CE, et al. Ascites microenvironment conditions the peritoneal pre-metastatic niche to promote the implantation of ovarian tumor spheroids: Involvement of fibrinogen\/fibrin and alphaV and alpha5beta1 integrins. Exp Cell Res. 2024;441(1):114155.","journal-title":"Exp Cell Res"},{"issue":"4","key":"2438_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1604","volume":"14","author":"F Neuhaus","year":"2024","unstructured":"Neuhaus F, Lieber S, Shinkevich V, Steitz AM, Raifer H, Roth K, et al. Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cells. Clin Transl Med. 2024;14(4):e1604.","journal-title":"Clin Transl Med"},{"issue":"8","key":"2438_CR53","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/ijc.32854","volume":"146","author":"M Yoshihara","year":"2020","unstructured":"Yoshihara M, Kajiyama H, Yokoi A, Sugiyama M, Koya Y, Yamakita Y, et al. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1\/Akt signaling pathway. Int J Cancer. 2020;146(8):2268\u201380.","journal-title":"Int J Cancer"},{"issue":"3","key":"2438_CR54","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ygyno.2005.02.017","volume":"97","author":"S Stadlmann","year":"2005","unstructured":"Stadlmann S, Amberger A, Pollheimer J, Gastl G, Offner FA, Margreiter R, et al. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol. 2005;97(3):784\u20139.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2438_CR55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000063801","volume":"63","author":"H Kajiyama","year":"2002","unstructured":"Kajiyama H, Kikkawa F, Maeda O, Suzuki T, Ino K, Mizutani S. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology. 2002;63(2):158\u201365.","journal-title":"Oncology"},{"issue":"8","key":"2438_CR56","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","volume":"4","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wang X, Cheng X, Liu Z, Yin Y, Li X, et al. Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nat Cancer. 2023;4(8):1138\u201356.","journal-title":"Nat Cancer"},{"issue":"7","key":"2438_CR57","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","volume":"39","author":"M Hornburg","year":"2021","unstructured":"Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021;39(7):928-44 e6.","journal-title":"Cancer Cell."},{"issue":"1","key":"2438_CR58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2012.07.020","volume":"326","author":"M Castells","year":"2012","unstructured":"Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I, et al. Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett. 2012;326(1):59\u201368.","journal-title":"Cancer Lett"},{"issue":"1","key":"2438_CR59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12967-014-0271-5","volume":"12","author":"C Touboul","year":"2014","unstructured":"Touboul C, Vidal F, Pasquier J, Lis R, Rafii A. Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med. 2014;12(1):271.","journal-title":"J Transl Med"},{"issue":"1","key":"2438_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1423-0127-19-23","volume":"19","author":"CM Ho","year":"2012","unstructured":"Ho CM, Chang SF, Hsiao CC, Chien TY, Shih DT. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. J Biomed Sci. 2012;19(1):23.","journal-title":"J Biomed Sci"},{"issue":"3","key":"2438_CR61","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ijc.25619","volume":"128","author":"R Lis","year":"2011","unstructured":"Lis R, Touboul C, Mirshahi P, Ali F, Mathew S, Nolan DJ, et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer. 2011;128(3):715\u201325.","journal-title":"Int J Cancer"},{"key":"2438_CR62","doi-asserted-by":"publisher","unstructured":"Raghavan S, Snyder CS, Wang A, McLean K, Zamarin D, Buckanovich RJ,\u00a0Mehta G.Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling. Cancers (Basel). 2020 Jul 27;12(8):2063. https:\/\/doi.org\/10.3390\/cancers12082063.\u00a0PMID: 32726910; PMCID: PMC7464970.","DOI":"10.3390\/cancers12082063"},{"issue":"10","key":"2438_CR63","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1111\/cas.15100","volume":"112","author":"K Wang","year":"2021","unstructured":"Wang K, Liu S, Dou Z, Zhang S, Yang X. Loss of Kruppel-like factor 9 facilitates stemness in ovarian cancer ascites-derived multicellular spheroids via Notch1\/slug signaling. Cancer Sci. 2021;112(10):4220\u201333.","journal-title":"Cancer Sci"},{"key":"2438_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-359","volume":"12","author":"M Wintzell","year":"2012","unstructured":"Wintzell M, Hjerpe E, Avall Lundqvist E, Shoshan M. Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer. 2012;12:359.","journal-title":"BMC Cancer"},{"issue":"16","key":"2438_CR65","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","volume":"28","author":"J Xu","year":"2022","unstructured":"Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y, et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin Cancer Res. 2022;28(16):3590\u2013602.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2438_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112153","volume":"394","author":"M Li","year":"2020","unstructured":"Li M, Wang J, Wang C, Xia L, Xu J, Xie X, et al. Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived COL1A1 and facilitates ovarian cancer metastasis. Exp Cell Res. 2020;394(1):112153.","journal-title":"Exp Cell Res"},{"issue":"10","key":"2438_CR67","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1158\/1541-7786.MCR-21-0565","volume":"20","author":"N Loret","year":"2022","unstructured":"Loret N, Vandamme N, De Coninck J, Taminau J, De Clercq K, Blancke G, et al. Distinct transcriptional programs in ascitic and solid cancer cells induce different responses to chemotherapy in high-grade serous ovarian cancer. Mol Cancer Res. 2022;20(10):1532\u201347.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2438_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02289-3","volume":"8","author":"M Schelker","year":"2017","unstructured":"Schelker M, Feau S, Du J, Ranu N, Klipp E, MacBeath G, et al. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. Nat Commun. 2017;8(1):2032.","journal-title":"Nat Commun"},{"key":"2438_CR69","doi-asserted-by":"publisher","unstructured":"Li Y, Wang W, Wang D, Zhang L, Wang X, He J,\u00a0Cao L, Li K, Xie H. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer. Genes (Basel). 2022 Dec 2;13(12):2276. https:\/\/doi.org\/10.3390\/genes13122276.\u00a0PMID: 36553542; PMCID: PMC9778425.","DOI":"10.3390\/genes13122276"},{"issue":"5","key":"2438_CR70","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mc.23289","volume":"60","author":"S Kim","year":"2021","unstructured":"Kim S, Han Y, Kim SI, Lee J, Jo H, Wang W, et al. Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer. Mol Carcinog. 2021;60(5):297\u2013312.","journal-title":"Mol Carcinog"},{"issue":"1","key":"2438_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ijc.28335","volume":"134","author":"S Reinartz","year":"2014","unstructured":"Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134(1):32\u201342.","journal-title":"Int J Cancer"},{"issue":"13","key":"2438_CR72","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","volume":"110","author":"D Duluc","year":"2007","unstructured":"Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110(13):4319\u201330.","journal-title":"Blood"},{"issue":"2","key":"2438_CR73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ijc.24401","volume":"125","author":"D Duluc","year":"2009","unstructured":"Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009;125(2):367\u201373.","journal-title":"Int J Cancer"},{"issue":"12","key":"2438_CR74","doi-asserted-by":"publisher","first-page":"e2411314","DOI":"10.1002\/advs.202411314","volume":"12","author":"H Luo","year":"2025","unstructured":"Luo H, She X, Zhang Y, Xie B, Zhang S, Li Q, et al. PLIN2 promotes lipid accumulation in ascites-associated macrophages and ovarian cancer progression by HIF1alpha\/SPP1 signaling. Adv Sci (Weinh). 2025;12(12):e2411314.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"2438_CR75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"2438_CR76","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"2438_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.21147\/j.issn.1000-9604.2025.01.06","volume":"37","author":"T He","year":"2025","unstructured":"He T, Zhang J, Zeng L, Yin Z, Yu B, Zhang X, et al. Composite score of PD-1 (+) CD8 (+) tumor-infiltrating lymphocytes and CD57 (+) CD8 (+) tumor ascites lymphocytes is associated with prognosis and tumor immune microenvironment of patients with advanced high-grade serous ovarian cancer. Chin J Cancer Res. 2025;37(1):73\u201389.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"2438_CR78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","volume":"64","author":"J Landskron","year":"2015","unstructured":"Landskron J, Helland O, Torgersen KM, Aandahl EM, Gjertsen BT, Bjorge L, et al. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother. 2015;64(3):337\u201347.","journal-title":"Cancer Immunol Immunother"},{"key":"2438_CR79","doi-asserted-by":"publisher","unstructured":"Bernson E, Huhn O, Karlsson V, Hawkes D, Lycke M, Cazzetta V,\u00a0Mikulak J, Hall J, PiskorzAM, Portuesi R, Vitobello D, Fiamengo B, Siesto G, Horowitz A, Ghadially H, Mavilio D, Brenton JD,Sundfeldt K, Colucci F. Identification of Tissue-Resident Natural Killer and T Lymphocytes withAnti-Tumor Properties in Ascites of Ovarian Cancer Patients. Cancers (Basel). 2023 Jun27;15(13):3362. https:\/\/doi.org\/10.3390\/cancers15133362.\u00a0PMID: 37444472; PMCID: PMC10340516.","DOI":"10.3390\/cancers15133362"},{"issue":"107","key":"2438_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adr4795","volume":"10","author":"K Slattery","year":"2025","unstructured":"Slattery K, Yao CH, Mylod E, Scanlan J, Scott B, Crowley JP, et al. Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer. Sci Immunol. 2025;10(107):eadr4795.","journal-title":"Sci Immunol"},{"key":"2438_CR81","doi-asserted-by":"publisher","first-page":"1448041","DOI":"10.3389\/fimmu.2024.1448041","volume":"15","author":"RJA Maas","year":"2024","unstructured":"Maas RJA, Hoogstad-van Evert JS, Hagemans IM, Brummelman J, van Ens D, de Jonge P, et al. Increased peritoneal TGF-beta1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer. Front Immunol. 2024;15:1448041.","journal-title":"Front Immunol"},{"issue":"1","key":"2438_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09534-z","volume":"22","author":"S Sato","year":"2022","unstructured":"Sato S, Matsushita H, Shintani D, Kobayashi Y, Fujieda N, Yabuno A, et al. Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer. BMC Cancer. 2022;22(1):437.","journal-title":"BMC Cancer"},{"key":"2438_CR83","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.3389\/fimmu.2018.03156","volume":"9","author":"C Wefers","year":"2018","unstructured":"Wefers C, Duiveman-de Boer T, Yigit R, Zusterzeel PLM, van Altena AM, Massuger L, et al. Survival of ovarian cancer patients is independent of the presence of DC and T cell subsets in ascites. Front Immunol. 2018;9:3156.","journal-title":"Front Immunol"},{"key":"2438_CR84","doi-asserted-by":"publisher","unstructured":"Prat M, Le Naour A, Coulson K, Lemee F, Leray H, Jacquemin G, Rahabi MC, Lemaitre L,Authier H, Ferron G, Barret JM, Martinez A, Ayyoub M, Delord JP, Gladieff L, Tabah-Fisch I, ProstJF, Couderc B, Coste A. Circulating CD14high CD16low intermediate blood monocytes as abiomarker of ascites immune status and ovarian cancer progression. J Immunother Cancer. 2020Jun;8(1):e000472. https:\/\/doi.org\/10.1136\/jitc-2019-000472.\u00a0PMID: 32503947; PMCID: PMC7279676.","DOI":"10.1136\/jitc-2019-000472"},{"issue":"10","key":"2438_CR85","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1158\/2326-6066.CIR-18-0578","volume":"7","author":"CS Tannenbaum","year":"2019","unstructured":"Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, et al. Mediators of inflammation-driven expansion, trafficking, and function of tumor-infiltrating MDSCs. Cancer Immunol Res. 2019;7(10):1687\u201399.","journal-title":"Cancer Immunol Res"},{"key":"2438_CR86","doi-asserted-by":"publisher","first-page":"643815","DOI":"10.3389\/fonc.2021.643815","volume":"11","author":"P Kanikarla Marie","year":"2021","unstructured":"Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, et al. The provocative roles of platelets in liver disease and cancer. Front Oncol. 2021;11:643815.","journal-title":"Front Oncol"},{"issue":"5","key":"2438_CR87","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/jcsm.13289","volume":"14","author":"CS Weng","year":"2023","unstructured":"Weng CS, Huang WC, Chang CL, Jan YT, Chen TC, Lee J. Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced-stage ovarian cancer. J Cachexia Sarcopenia Muscle. 2023;14(5):2114\u201325.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2438_CR88","doi-asserted-by":"publisher","unstructured":"Bortot B, Mangogna A, Peacock B, Lees R, Valle F, Brucale M, Tassinari S, Romano F, Ricci G, Biffi S. Platelet Activation in Ovarian Cancer Ascites: Assessment of GPIIb\/IIIa and PF4 in Small Extracellular Vesicles by Nano-Flow Cytometry Analysis. Cancers (Basel). 2022 Aug24;14(17):4100. https:\/\/doi.org\/10.3390\/cancers14174100.\u00a0PMID: 36077635; PMCID: PMC9454670.","DOI":"10.3390\/cancers14174100"},{"key":"2438_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1304-z","volume":"15","author":"R Orellana","year":"2015","unstructured":"Orellana R, Kato S, Erices R, Bravo ML, Gonzalez P, Oliva B, et al. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer. 2015;15:290.","journal-title":"BMC Cancer"},{"issue":"6","key":"2438_CR90","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-10-2429","volume":"17","author":"S Liao","year":"2011","unstructured":"Liao S, Liu J, Lin P, Shi T, Jain RK, Xu L. TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res. 2011;17(6):1415\u201324.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2438_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42593-9","volume":"14","author":"A Yokoi","year":"2023","unstructured":"Yokoi A, Yoshida K, Koga H, Kitagawa M, Nagao Y, Iida M, et al. Spatial exosome analysis using cellulose nanofiber sheets reveals the location heterogeneity of extracellular vesicles. Nat Commun. 2023;14(1):6915.","journal-title":"Nat Commun"},{"issue":"1","key":"2438_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01177-7","volume":"31","author":"F Gorini","year":"2025","unstructured":"Gorini F, Coada CA, Monesmith S, De Leo A, de Biase D, Dondi G, et al. Distinctive features of blood- and ascitic fluid-derived extracellular vesicles in ovarian cancer patients. Mol Med. 2025;31(1):143.","journal-title":"Mol Med"},{"issue":"1","key":"2438_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-018-0391-2","volume":"11","author":"CM Yamamoto","year":"2018","unstructured":"Yamamoto CM, Oakes ML, Murakami T, Muto MG, Berkowitz RS, Ng SW. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. J Ovarian Res. 2018;11(1):20.","journal-title":"J Ovarian Res"},{"key":"2438_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718408","volume":"11","author":"A Gonda","year":"2021","unstructured":"Gonda A, Zhao N, Shah JV, Siebert JN, Gunda S, Inan B, et al. Extracellular vesicle molecular signatures characterize metastatic dynamicity in ovarian cancer. Front Oncol. 2021;11:718408.","journal-title":"Front Oncol"},{"key":"2438_CR95","doi-asserted-by":"publisher","first-page":"9653194","DOI":"10.1155\/2017\/9653194","volume":"2017","author":"AT Reiner","year":"2017","unstructured":"Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, et al. EV-associated mmp9 in high-grade serous ovarian cancer is preferentially localized to annexin V-binding EVs. Dis Markers. 2017;2017:9653194.","journal-title":"Dis Markers"},{"key":"2438_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1142755","volume":"13","author":"L Kong","year":"2023","unstructured":"Kong L, Xu F, Yao Y, Gao Z, Tian P, Zhuang S, et al. Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer. Front Oncol. 2023;13:1142755.","journal-title":"Front Oncol"},{"issue":"1","key":"2438_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04695-7","volume":"9","author":"MKS Tang","year":"2018","unstructured":"Tang MKS, Yue PYK, Ip PP, Huang RL, Lai HC, Cheung ANY, et al. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nat Commun. 2018;9(1):2270.","journal-title":"Nat Commun"},{"issue":"28","key":"2438_CR98","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1038\/s41388-018-0189-0","volume":"37","author":"KDP Dorayappan","year":"2018","unstructured":"Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, et al. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3\/Rab proteins. Oncogene. 2018;37(28):3806\u201321.","journal-title":"Oncogene"},{"issue":"1","key":"2438_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01413-9","volume":"22","author":"L Gong","year":"2024","unstructured":"Gong L, Li G, Yi X, Han Q, Wu Q, Ying F, et al. Tumor-derived small extracellular vesicles facilitate omental metastasis of ovarian cancer by triggering activation of mesenchymal stem cells. Cell Commun Signal. 2024;22(1):47.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"2438_CR100","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s44321-024-00069-3","volume":"16","author":"A Gambelli","year":"2024","unstructured":"Gambelli A, Nespolo A, Rampioni Vinciguerra GL, Pivetta E, Pellarin I, Nicoloso MS, et al. Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer. EMBO Mol Med. 2024;16(5):1162\u201392.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2438_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49512-6","volume":"15","author":"VO Shender","year":"2024","unstructured":"Shender VO, Anufrieva KS, Shnaider PV, Arapidi GP, Pavlyukov MS, Ivanova OM, et al. Therapy-induced secretion of spliceosomal components mediates pro-survival crosstalk between ovarian cancer cells. Nat Commun. 2024;15(1):5237.","journal-title":"Nat Commun"},{"key":"2438_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadva.2025.100140","volume":"7","author":"KM Bienes","year":"2025","unstructured":"Bienes KM, Yokoi A, Kitagawa M, Kajiyama H, Thaysen-Andersen M, Kawahara R. Extracellular vesicles display distinct glycosignatures in high-grade serous ovarian carcinoma. BBA Adv. 2025;7:100140.","journal-title":"BBA Adv"},{"issue":"10","key":"2438_CR103","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.21037\/tcr-24-789","volume":"13","author":"G Xie","year":"2024","unstructured":"Xie G, Zhang Y, Ma J, Guo X, Xu J, Chen L, et al. Exosomal AHSG in ovarian cancer ascites inhibits malignant progression of ovarian cancer by p53\/FAK\/Src signaling. Transl Cancer Res. 2024;13(10):5365\u201380.","journal-title":"Transl Cancer Res"},{"issue":"2","key":"2438_CR104","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/2326-6066.CIR-17-0113","volume":"6","author":"GN Shenoy","year":"2018","unstructured":"Shenoy GN, Loyall J, Maguire O, Iyer V, Kelleher RJ Jr., Minderman H, et al. Exosomes associated with human ovarian tumors harbor a reversible checkpoint of T-cell responses. Cancer Immunol Res. 2018;6(2):236\u201347.","journal-title":"Cancer Immunol Res"},{"key":"2438_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-017-0430-x","volume":"17","author":"Q Wu","year":"2017","unstructured":"Wu Q, Wu X, Ying X, Zhu Q, Wang X, Jiang L, et al. Suppression of endothelial cell migration by tumor associated macrophage-derived exosomes is reversed by epithelial ovarian cancer exosomal lncRNA. Cancer Cell Int. 2017;17:62.","journal-title":"Cancer Cell Int"},{"key":"2438_CR106","volume":"26","author":"AN Aquino-Acevedo","year":"2022","unstructured":"Aquino-Acevedo AN, Knochenhauer H, Castillo-Ocampo Y, Ortiz-Leon M, Rivera-Lopez YA, Morales-Lopez C, et al. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer. Brain Behav Immun. 2022;26:100558.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"2438_CR107","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12079-022-00698-8","volume":"17","author":"Z Geng","year":"2023","unstructured":"Geng Z, Pan X, Xu J, Jia X. Friend and foe: the regulation network of ascites components in ovarian cancer progression. J Cell Commun Signal. 2023;17(3):391\u2013407.","journal-title":"J Cell Commun Signal"},{"issue":"8","key":"2438_CR108","first-page":"2875","volume":"29","author":"RL Giuntoli 2nd","year":"2009","unstructured":"Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29(8):2875\u201384.","journal-title":"Anticancer Res"},{"key":"2438_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071702","author":"CR Tonetti","year":"2021","unstructured":"Tonetti CR, de Souza-Araujo CN, Yoshida A, da Silva RF, Alves PCM, Mazzola TN, et al. Ovarian cancer-associated ascites have high proportions of cytokine-responsive CD56bright NK cells. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10071702.","journal-title":"Cells"},{"key":"2438_CR110","doi-asserted-by":"publisher","unstructured":"Guigue PA, Brezinov Y, Yasmeen A, Mbarik M, Salvador S, Lau S,\u00a0Gotlieb WH, Brodeur MN. Ascites and Serum Interleukin-10 Levels as a Prognostic Tool for Ovarian Cancer Outcomes. Cancers (Basel). 2024 Aug 14;16(16):2840.. https:\/\/doi.org\/10.3390\/cancers16162840.","DOI":"10.3390\/cancers16162840"},{"key":"2438_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-210","volume":"11","author":"D Lane","year":"2011","unstructured":"Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210.","journal-title":"BMC Cancer"},{"issue":"1","key":"2438_CR112","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.canlet.2010.02.019","volume":"295","author":"Y Wang","year":"2010","unstructured":"Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010;295(1):110\u201323.","journal-title":"Cancer Lett"},{"issue":"5","key":"2438_CR113","first-page":"6457","volume":"15","author":"Y Imai","year":"2018","unstructured":"Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, et al. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett. 2018;15(5):6457\u201368.","journal-title":"Oncol Lett"},{"issue":"1","key":"2438_CR114","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/1878-0261.13726","volume":"19","author":"K Bischof","year":"2025","unstructured":"Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, et al. Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways. Mol Oncol. 2025;19(1):81\u201398.","journal-title":"Mol Oncol"},{"key":"2438_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101939","volume":"44","author":"YK Carmi","year":"2024","unstructured":"Carmi YK, Agbarya A, Khamaisi H, Farah R, Shechtman Y, Korobochka R, et al. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells. Transl Oncol. 2024;44:101939.","journal-title":"Transl Oncol"},{"issue":"2","key":"2438_CR116","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cyto.2011.06.005","volume":"56","author":"Y Wang","year":"2011","unstructured":"Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine. 2011;56(2):365\u201375.","journal-title":"Cytokine"},{"issue":"1","key":"2438_CR117","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2013.07.105","volume":"131","author":"YL Chen","year":"2013","unstructured":"Chen YL, Cheng WF, Chang MC, Lin HW, Huang CT, Chien CL, et al. Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecol Oncol. 2013;131(1):63\u20138.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2438_CR118","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1530\/ERC-15-0145","volume":"22","author":"YL Chen","year":"2015","unstructured":"Chen YL, Chou CY, Chang MC, Lin HW, Huang CT, Hsieh SF, et al. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients. Endocr Relat Cancer. 2015;22(5):703\u201311.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2438_CR119","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2198185","volume":"12","author":"PG Pavicic Jr.","year":"2023","unstructured":"Pavicic PG Jr., Rayman PA, Swaidani S, Rupani A, Makarov V, Tannenbaum CS, et al. Immunotherapy with IL12 and PD1\/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression. Oncoimmunology. 2023;12(1):2198185.","journal-title":"Oncoimmunology"},{"key":"2438_CR120","doi-asserted-by":"publisher","unstructured":"Murphy B, Miyamoto T, Manning BS, Mirji G, Ugolini A, Kannan T,\u00a0Hamada K, Zhu YP,Claiborne DT, Huang L, Zhang R, Nefedova Y, Kossenkov A, Veglia F, Shinde R, Zhang N. Myeloidactivation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer. JExp Med. 2024 Dec 2;221(12):e20231967. doi: 10.1084\/jem.20231967. Epub 2024 Nov 21.Erratum in: J Exp Med. 2025 Apr 7;222(4):e2023196702272025c. https:\/\/doi.org\/10.1084\/jem.20231967.\u00a0PMID: 39570374; PMCID: PMC11586802","DOI":"10.1084\/jem.20231967"},{"issue":"1","key":"2438_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0542-2","volume":"15","author":"D Lane","year":"2016","unstructured":"Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, et al. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol Cancer. 2016;15(1):58.","journal-title":"Mol Cancer"},{"issue":"27","key":"2438_CR122","doi-asserted-by":"publisher","first-page":"24584","DOI":"10.1074\/jbc.M112275200","volume":"277","author":"E Schutyser","year":"2002","unstructured":"Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18\/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem. 2002;277(27):24584\u201393.","journal-title":"J Biol Chem"},{"issue":"4","key":"2438_CR123","doi-asserted-by":"publisher","first-page":"e1412029","DOI":"10.1080\/2162402X.2017.1412029","volume":"7","author":"M Idorn","year":"2018","unstructured":"Idorn M, Olsen M, Halldorsdottir HR, Skadborg SK, Pedersen M, Hogdall C, et al. Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. Oncoimmunology. 2018;7(4):e1412029.","journal-title":"Oncoimmunology"},{"key":"2438_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1506236","volume":"15","author":"V Karlsson","year":"2024","unstructured":"Karlsson V, Stal E, Stoopendahl E, Ivarsson A, Leffler H, Lycke M, et al. Elevated galectin-3 levels in the tumor microenvironment of ovarian cancer - implication of ROS mediated suppression of NK cell antitumor response via tumor-associated neutrophils. Front Immunol. 2024;15:1506236.","journal-title":"Front Immunol"},{"issue":"11","key":"2438_CR125","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498\u2013503.","journal-title":"Nat Med"},{"issue":"3","key":"2438_CR126","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053\u201364.","journal-title":"Am J Pathol"},{"key":"2438_CR127","doi-asserted-by":"publisher","unstructured":"Wr\u00f3blewski M, Szewczyk-Golec K, Ho\u0142y\u0144\u0144ska-Iwan I, Wr\u00f3\u00f3blewska J, Wo\u017a\u017aniak A.Characteristics of Selected Adipokines in Ascites and Blood of Ovarian Cancer Patients. Cancers(Basel). 2021 Sep 20;13(18):4702. https:\/\/doi.org\/10.3390\/cancers13184702. PMID: 34572929; PMCID:PMC8465310.","DOI":"10.3390\/cancers13184702"},{"issue":"2","key":"2438_CR128","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/ijc.29385","volume":"137","author":"I Matte","year":"2015","unstructured":"Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piche A. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms. Int J Cancer. 2015;137(2):289\u201398.","journal-title":"Int J Cancer"},{"issue":"5","key":"2438_CR129","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s13402-016-0289-1","volume":"39","author":"J Mikula-Pietrasik","year":"2016","unstructured":"Mikula-Pietrasik J, Uruski P, Matuszkiewicz K, Szubert S, Moszynski R, Szpurek D, et al. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells. Cell Oncol (Dordr). 2016;39(5):473\u201381.","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"2438_CR130","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s11357-023-01056-1","volume":"46","author":"D Szeocs","year":"2024","unstructured":"Szeocs D, Vida B, Petovari G, Poliska S, Janka E, Sipos A, et al. Cell-free ascites from ovarian cancer patients induces warburg metabolism and cell proliferation through TGFbeta-ERK signaling. Geroscience. 2024;46(4):3581\u201397.","journal-title":"Geroscience"},{"key":"2438_CR131","doi-asserted-by":"publisher","unstructured":"Valdivia A, Isac AM, Cardenas H, Zhao G, Zhang Y, Huang H,\u00a0Wei JJ, Cuello-Fredes M, Kato S, G\u00f3\u00f3mez-Valenzuela F, Gourronc F, Klingelhutz A, Matei D. Complement activation at the interface between adipocytes and cancer cells drives tumor progression. JCI Insight. 2025\u00a0Feb 18;10(6):e184935. https:\/\/doi.org\/10.1172\/jci.insight.184935.\u00a0PMID: 39964754; PMCID: PMC11949041.","DOI":"10.1172\/jci.insight.184935"},{"issue":"2\u20133","key":"2438_CR132","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12307-018-0215-3","volume":"11","author":"D Lane","year":"2018","unstructured":"Lane D, Matte I, Garde-Granger P, Bessette P, Piche A. Ascites IL-10 promotes ovarian cancer cell migration. Cancer Microenviron. 2018;11(2\u20133):115\u201324.","journal-title":"Cancer Microenviron"},{"issue":"1","key":"2438_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-025-00391-5","volume":"13","author":"S Deng","year":"2025","unstructured":"Deng S, Kim W, Cheng K, Yang Q, Singh Y, Bae G, et al. Identification and impact of microbiota-derived metabolites in ascites of ovarian and gastrointestinal cancer. Cancer Metab. 2025;13(1):21.","journal-title":"Cancer Metab"},{"issue":"9","key":"2438_CR134","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/cas.12987","volume":"107","author":"S Kim","year":"2016","unstructured":"Kim S, Kim B, Song YS. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016;107(9):1173\u20138.","journal-title":"Cancer Sci"},{"key":"2438_CR135","doi-asserted-by":"publisher","unstructured":"Uno K, Iyoshi S, Yoshihara M, Kitami K, Mogi K,\u00a0Fujimoto H, Sugiyama M, Koya Y, YamakitaY, Nawa A, Kanayama T, Tomita H, Enomoto A, Kajiyama H. Metastatic Voyage of Ovarian CancerCells in Ascites with the Assistance of Various Cellular Components. Int J Mol Sci. 2022 Apr15;23(8):4383. https:\/\/doi.org\/10.3390\/ijms23084383.\u00a0PMID: 35457198; PMCID: PMC9031612","DOI":"10.3390\/ijms23084383"},{"key":"2438_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.109949","volume":"81","author":"M Pitman","year":"2021","unstructured":"Pitman M, Oehler MK, Pitson SM. Sphingolipids as multifaceted mediators in ovarian cancer. Cell Signal. 2021;81:109949.","journal-title":"Cell Signal"},{"issue":"12","key":"2438_CR137","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1074\/mcp.M114.041194","volume":"13","author":"VO Shender","year":"2014","unstructured":"Shender VO, Pavlyukov MS, Ziganshin RH, Arapidi GP, Kovalchuk SI, Anikanov NA, et al. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteomics. 2014;13(12):3558\u201371.","journal-title":"Mol Cell Proteomics"},{"key":"2438_CR138","volume":"39","author":"DL Almeida-Nunes","year":"2024","unstructured":"Almeida-Nunes DL, Nunes M, Osorio H, Ferreira V, Lobo C, Monteiro P, et al. Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression. Biochem Biophys Rep. 2024;39:101755.","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"2438_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00558-8","volume":"13","author":"H Wang","year":"2024","unstructured":"Wang H, Yung MM, Xuan Y, Chen F, Chan W, Siu MK, et al. Polyunsaturated fatty acids promote M2-like TAM deposition via dampening RhoA-YAP1 signaling in the ovarian cancer microenvironment. Exp Hematol Oncol. 2024;13(1):90.","journal-title":"Exp Hematol Oncol"},{"key":"2438_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2024.07.001","volume":"189","author":"O Graham","year":"2024","unstructured":"Graham O, Rodriguez J, Abbott R, Lomonosova E, Fashemi B, Drexler R, et al. A toolkit for a modern gynecologic oncology tissue bank. Gynecol Oncol. 2024;189:1\u20138.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"2438_CR141","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1016\/j.celrep.2017.03.015","volume":"18","author":"C Francavilla","year":"2017","unstructured":"Francavilla C, Lupia M, Tsafou K, Villa A, Kowalczyk K, Rakownikow Jersie-Christensen R, et al. Phosphoproteomics of primary cells reveals druggable kinase signatures in ovarian cancer. Cell Rep. 2017;18(13):3242\u201356.","journal-title":"Cell Rep"},{"key":"2438_CR142","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-1-0716-1956-8_5","volume":"2424","author":"HM Micek","year":"2022","unstructured":"Micek HM, Carroll MJ, Barroilhet L, Kreeger PK. Processing and analysis of ascites. Methods Mol Biol. 2022;2424:95\u2013104.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2438_CR143","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41418-021-00878-w","volume":"29","author":"T Velletri","year":"2022","unstructured":"Velletri T, Villa CE, Cilli D, Barzaghi B, Lo Riso P, Lupia M, et al. Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer. Cell Death Differ. 2022;29(3):614\u201326.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2438_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00463-z","volume":"7","author":"E Akerlund","year":"2023","unstructured":"Akerlund E, Gudoityte G, Moussaud-Lamodiere E, Lind O, Bwanika HC, Lehti K, et al. The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients. NPJ Precis Oncol. 2023;7(1):111.","journal-title":"NPJ Precis Oncol"},{"issue":"19","key":"2438_CR145","doi-asserted-by":"publisher","first-page":"19714","DOI":"10.1002\/cam4.6521","volume":"12","author":"WS Chan","year":"2023","unstructured":"Chan WS, Mo X, Ip PPC, Tse KY. Patient-derived organoid culture in epithelial ovarian cancers-techniques, applications, and future perspectives. Cancer Med. 2023;12(19):19714\u201331.","journal-title":"Cancer Med"},{"key":"2438_CR146","doi-asserted-by":"crossref","unstructured":"Cerne K, Kelhar N, Resnik N, Herzog M, Vodnik L, Veranic P, et al. Characteristics of extracellular vesicles from a high-grade serous ovarian cancer cell line derived from a platinum-resistant patient as a potential tool for aiding the prediction of responses to chemotherapy. Pharmaceuticals (Basel). 2023;16(6).","DOI":"10.3390\/ph16060907"},{"key":"2438_CR147","doi-asserted-by":"publisher","unstructured":"Maru Y, Hippo Y. Current Status of Patient-Derived Ovarian Cancer Models. Cells. 2019 May 25;8(5):505.\u00a0https:\/\/doi.org\/10.3390\/cells8050505. PMID: 31130643; PMCID: PMC6562658.","DOI":"10.3390\/cells8050505"},{"key":"2438_CR148","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2147\/IJWH.S405010","volume":"15","author":"W Chen","year":"2023","unstructured":"Chen W, Fang PH, Zheng B, Liang Y, Mao Y, Jiang X, et al. Effective treatment for recurrent ovarian cancer guided by drug sensitivity from ascites-derived organoid: a case report. Int J Womens Health. 2023;15:1047\u201357.","journal-title":"Int J Womens Health"},{"issue":"1","key":"2438_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12429-w","volume":"24","author":"L Thorel","year":"2024","unstructured":"Thorel L, Divoux J, Lequesne J, Babin G, Morice PM, Florent R, et al. The OVAREX study: establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers. BMC Cancer. 2024;24(1):701.","journal-title":"BMC Cancer"},{"key":"2438_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010001","author":"I Psilopatis","year":"2022","unstructured":"Psilopatis I, Sykaras AG, Mandrakis G, Vrettou K, Theocharis S. Patient-derived organoids: the beginning of a new era in ovarian cancer disease modeling and drug sensitivity testing. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines11010001.","journal-title":"Biomedicines"},{"issue":"8","key":"2438_CR151","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm1831","volume":"8","author":"K Zhang","year":"2022","unstructured":"Zhang K, Erkan EP, Jamalzadeh S, Dai J, Andersson N, Kaipio K, et al. Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. Sci Adv. 2022;8(8):eabm1831.","journal-title":"Sci Adv"},{"issue":"7","key":"2438_CR152","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perreard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56(7):1531\u201351.","journal-title":"Exp Mol Med"},{"issue":"11","key":"2438_CR153","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202404117","volume":"14","author":"N Karimnia","year":"2025","unstructured":"Karimnia N, Wilson AL, Doran BR, Do J, Matthews A, Ho GY, et al. A novel 3D high-throughput phenotypic drug screening pipeline to identify drugs with repurposing potential for the treatment of ovarian cancer. Adv Healthc Mater. 2025;14(11):e2404117.","journal-title":"Adv Healthc Mater"},{"key":"2438_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217738","volume":"625","author":"D Duraki","year":"2025","unstructured":"Duraki D, Jabeen M, Mao C, Wang L, Ghosh S, Dai X, et al. A necrosis inducer promotes an immunogenic response and destroys ovarian cancers in mouse xenografts and patient ascites organoids. Cancer Lett. 2025;625:217738.","journal-title":"Cancer Lett"},{"key":"2438_CR155","doi-asserted-by":"publisher","unstructured":"Arias-Diaz AE, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Banobre J, Casas-Arozamena C,\u00a0Muinelo-Romay L, Lopez-Lopez R, Vilar A, Curiel T, Abal M. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas. Int J Mol Sci. 2023 Aug 25;24(17):13208. https:\/\/doi.org\/10.3390\/ijms241713208.\u00a0PMID: 37686015; PMCID:PMC10487816.","DOI":"10.3390\/ijms241713208"},{"key":"2438_CR156","doi-asserted-by":"publisher","unstructured":"Graham O, Rodriguez J, van Biljon L, Fashemi B, Graham E, Fuh K,Khabele D, Mullen M. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids. J Vis Exp. 2023 Jan 6;(191):10.3791\/64878.\u00a0https:\/\/doi.org\/10.3791\/64878. PMID: 36688549; PMCID:PMC10881225.","DOI":"10.3791\/64878"},{"key":"2438_CR157","doi-asserted-by":"publisher","unstructured":"Fashemi BE, van Biljon L, Rodriguez J, Graham O, Mullen M,\u00a0Khabele D. Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing. J Vis Exp. 2023 Sep 15;(199):10.3791\/65068. doi: https:\/\/doi.org\/10.3791\/65068. PMID: 37782106; PMCID: PMC10881228.","DOI":"10.3791\/65068."},{"issue":"6","key":"2438_CR158","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cels.2023.05.003","volume":"14","author":"DB Morse","year":"2023","unstructured":"Morse DB, Michalowski AM, Ceribelli M, De Jonghe J, Vias M, Riley D, et al. Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics. Cell Syst. 2023;14(6):464-81 e7.","journal-title":"Cell Syst."},{"issue":"6","key":"2438_CR159","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41388-021-02139-z","volume":"41","author":"T Kan","year":"2022","unstructured":"Kan T, Zhang S, Zhou S, Zhang Y, Zhao Y, Gao Y, et al. Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence. Oncogene. 2022;41(6):895\u2013906.","journal-title":"Oncogene"},{"key":"2438_CR160","doi-asserted-by":"publisher","unstructured":"J. Garcia FM, Geiguer F, Aurel JP, Puisieux A, Morel AP, Bardel C, Vilchez G, Brigitte M, Couraud S, Vigneron A, Tourniaire G, Payen-Gay LF. Whole transcriptomics analyses of mimicking circulating tumor cells (CTCs) by single-cell RNA sequencing (scRNAseq). Ann Oncol. 2019;30:Supplement 5, October 2019, v13.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdz238","DOI":"10.1093\/annonc\/mdz238"},{"key":"2438_CR161","doi-asserted-by":"publisher","unstructured":"Nishie R, Tanaka T, Hirosuna K, Miyamoto S, Murakami H, Tsuchihashi H,\u00a0Toji A, Ueda S,Morita N, Hashida S, Daimon A, Terada S, Maruoka H, Konishi H, Kogata Y, Taniguchi K, Komura K,Ohmichi M. Creation and Validation of Patient-Derived Cancer Model Using Peritoneal andPleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience. J Clin Med. 2024May 6;13(9):2718.\u00a0doi: https:\/\/doi.org\/10.3390\/jcm13092718. PMID: 38731247; PMCID: PMC11084603.","DOI":"10.3390\/jcm13092718"},{"issue":"5","key":"2438_CR162","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-16-1237","volume":"23","author":"JF Liu","year":"2017","unstructured":"Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res. 2017;23(5):1263\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2438_CR163","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.stemcr.2014.12.005","volume":"4","author":"BE McIntosh","year":"2015","unstructured":"McIntosh BE, Brown ME, Duffin BM, Maufort JP, Vereide DT, Slukvin II, et al. Nonirradiated NOD, B6.SCID Il2rgamma-\/- Kit(W41\/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells. Stem Cell Rep. 2015;4(2):171\u201380.","journal-title":"Stem Cell Rep."},{"issue":"2","key":"2438_CR164","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2767-9764.CRC-22-0300","volume":"3","author":"MP Steinkamp","year":"2023","unstructured":"Steinkamp MP, Lagutina I, Brayer KJ, Schultz F, Burke D, Pankratz VS, et al. Humanized patient-derived xenograft models of disseminated ovarian cancer recapitulate key aspects of the tumor immune environment within the peritoneal cavity. Cancer Res Commun. 2023;3(2):309\u201324.","journal-title":"Cancer Res Commun"},{"issue":"46","key":"2438_CR165","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp6567","volume":"10","author":"A Nespolo","year":"2024","unstructured":"Nespolo A, Stefenatti L, Pellarin I, Gambelli A, Rampioni Vinciguerra GL, Karimbayli J, et al. USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity. Sci Adv. 2024;10(46):eadp6567.","journal-title":"Sci Adv"},{"issue":"10","key":"2438_CR166","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1016\/j.bbagen.2013.06.023","volume":"1830","author":"L Carduner","year":"2013","unstructured":"Carduner L, Agniel R, Kellouche S, Picot CR, Blanc-Fournier C, Leroy-Dudal J, et al. Ovarian cancer ascites-derived vitronectin and fibronectin: combined purification, molecular features and effects on cell response. Biochim Biophys Acta. 2013;1830(10):4885\u201397.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2438_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28840-5","volume":"13","author":"S Sato","year":"2023","unstructured":"Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, et al. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Sci Rep. 2023;13(1):1537.","journal-title":"Sci Rep"},{"key":"2438_CR168","doi-asserted-by":"publisher","unstructured":"Grobben Y, den Ouden JE, Aguado C, van Altena AM, Kraneveld AD, Zaman GJR. Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1. Cancers (Basel). 2023\u00a0Jan 31;15(3):893. doi: https:\/\/doi.org\/10.3390\/cancers15030893. PMID: 36765849; PMCID: PMC9913486.","DOI":"10.3390\/cancers15030893"},{"issue":"13","key":"2438_CR169","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1039\/D1LC00177A","volume":"21","author":"YD Chung","year":"2021","unstructured":"Chung YD, Liu TH, Liang YL, Lin CN, Hsu KF, Lee GB. An integrated microfluidic platform for detection of ovarian clear cell carcinoma mRNA biomarker FXYD2. Lab Chip. 2021;21(13):2625\u201332.","journal-title":"Lab Chip"},{"issue":"15","key":"2438_CR170","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1074\/jbc.M116.746859","volume":"292","author":"PC Buchanan","year":"2017","unstructured":"Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, et al. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292(15):6339\u201351.","journal-title":"J Biol Chem"},{"issue":"2","key":"2438_CR171","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ygyno.2020.11.018","volume":"160","author":"E Hulstaert","year":"2021","unstructured":"Hulstaert E, Morlion A, Levanon K, Vandesompele J, Mestdagh P. Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: a systematic review. Gynecol Oncol. 2021;160(2):633\u201342.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2438_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13218-1","volume":"24","author":"S Iyoshi","year":"2024","unstructured":"Iyoshi S, Kimura M, Yoshihara M, Kunishima A, Miyamoto E, Fujimoto H, et al. Detailed analysis of the histology-specific impact of ascites volume on the outcome of epithelial ovarian cancer: a multi-institutional retrospective cohort study. BMC Cancer. 2024;24(1):1479.","journal-title":"BMC Cancer"},{"issue":"9","key":"2438_CR173","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1614856","volume":"8","author":"F Antony","year":"2019","unstructured":"Antony F, Deantonio C, Cotella D, Soluri MF, Tarasiuk O, Raspagliesi F, et al. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncoimmunology. 2019;8(9):e1614856.","journal-title":"Oncoimmunology"},{"key":"2438_CR174","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jprot.2017.02.001","volume":"157","author":"K Biskup","year":"2017","unstructured":"Biskup K, Braicu EI, Sehouli J, Tauber R, Blanchard V. The ascites N-glycome of epithelial ovarian cancer patients. J Proteomics. 2017;157:33\u20139.","journal-title":"J Proteomics"},{"key":"2438_CR175","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.dib.2018.12.056","volume":"22","author":"V Shender","year":"2019","unstructured":"Shender V, Arapidi G, Butenko I, Anikanov N, Ivanova O, Govorun V. Peptidome profiling dataset of ovarian cancer and non-cancer proximal fluids: ascites and blood sera. Data Brief. 2019;22:557\u201362.","journal-title":"Data Brief"},{"issue":"7","key":"2438_CR176","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1515\/cclm-2012-0642","volume":"51","author":"U Kuzmanov","year":"2013","unstructured":"Kuzmanov U, Musrap N, Kosanam H, Smith CR, Batruch I, Dimitromanolakis A, et al. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clin Chem Lab Med. 2013;51(7):1467\u201376.","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"2438_CR177","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1007\/s13277-015-4538-0","volume":"37","author":"X Wei","year":"2016","unstructured":"Wei X, Jin Y, Tian Y, Zhang H, Wu J, Lu W, et al. Regulatory b cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumor Biol. 2016;37(5):6581\u20138.","journal-title":"Tumor Biol"},{"key":"2438_CR178","doi-asserted-by":"publisher","unstructured":"Wang Y, He M, Zhang C, Cao K, Zhang G, Yang M, et al. Siglec-9+ tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer. J Immunother Cancer. 2023\u00a0Sep;11(9):e007099.. https:\/\/doi.org\/10.1136\/jitc-2023-007099.\u00a0PMID: 37709296; PMCID: PMC10503378.","DOI":"10.1136\/jitc-2023-007099"},{"key":"2438_CR179","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000472","author":"M Prat","year":"2020","unstructured":"Prat M, Le Naour A, Coulson K, Lemee F, Leray H, Jacquemin G, et al. Circulating CD14high CD16low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000472.","journal-title":"J Immunother Cancer"},{"key":"2438_CR180","doi-asserted-by":"publisher","unstructured":"da Silva RF, Yoshida A, Cardozo DM, Jales RM, Paust S, Derchain S,\u00a0Guimar\u00e3\u00e3es F. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence of Malignant Cells in Ovarian Cancer Patients. Int J Mol Sci. 2017 May 17;18(5):856. doi:https:\/\/doi.org\/10.3390\/ijms18050856. PMID: 28513532; PMCID: PMC5454809.","DOI":"10.3390\/ijms18050856"},{"key":"2438_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864021","volume":"12","author":"J Zhang","year":"2022","unstructured":"Zhang J, He T, Yin Z, Shang C, Xue L, Guo H. Ascitic senescent T cells are linked to chemoresistance in patients with advanced high-grade serous ovarian cancer. Front Oncol. 2022;12:864021.","journal-title":"Front Oncol"},{"issue":"1","key":"2438_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6321-x","volume":"19","author":"J Shi","year":"2019","unstructured":"Shi J, Huo R, Li N, Li H, Zhai T, Li H, et al. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer. 2019;19(1):1140.","journal-title":"BMC Cancer"},{"key":"2438_CR183","doi-asserted-by":"publisher","unstructured":"Zhou Y, Tian J, Shen Y, Liang H, Chen Y, Wang J,\u00a0Gu Y. sB7-H4 is a diagnostic biomarker inepithelial ovarian cancer and correlates to platinum resistance. Clin Exp Immunol. 2025 Jan21;219(1):uxae084. doi: https:\/\/doi.org\/10.1093\/cei\/uxae084.\u00a0PMID: 39373704; PMCID: PMC11771197.\u00a0","DOI":"10.1093\/cei\/uxae084"},{"key":"2438_CR184","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2024.12.006","volume":"193","author":"J Ricciuti","year":"2025","unstructured":"Ricciuti J, Liu Q, Khan A, Joseph JM, Veuskens B, Giridharan T, et al. Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer. Gynecol Oncol. 2025;193:49\u201357.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2438_CR185","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.neo.2019.01.001","volume":"21","author":"M Ullah","year":"2019","unstructured":"Ullah M, Azazzen D, Kaci R, Benabbou N, Pujade Lauraine E, Pocard M, et al. High expression of HLA-G in ovarian carcinomatosis: the role of interleukin-1beta. Neoplasia (New York, NY). 2019;21(3):331\u201342.","journal-title":"Neoplasia (New York, NY)"},{"key":"2438_CR186","doi-asserted-by":"publisher","unstructured":"Amer H, Kartikasari AER, Plebanski M. Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis. J Pers Med. 2021 Dec 9;11(12):1335.\u00a0https:\/\/doi.org\/10.3390\/jpm11121335. PMID: 34945807; PMCID: PMC8704427.","DOI":"10.3390\/jpm11121335"},{"key":"2438_CR187","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2018.03.019","volume":"482","author":"V Dalal","year":"2018","unstructured":"Dalal V, Kumar R, Kumar S, Sharma A, Kumar L, Sharma JB, et al. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clin Chim Acta. 2018;482:27\u201332.","journal-title":"Clin Chim Acta"},{"key":"2438_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1511-7","volume":"15","author":"D Lane","year":"2015","unstructured":"Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015;15:492.","journal-title":"BMC Cancer"},{"issue":"1","key":"2438_CR189","first-page":"160","volume":"9","author":"I Matte","year":"2019","unstructured":"Matte I, Garde-Granger P, Bessette P, Piche A. Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer. Am J Cancer Res. 2019;9(1):160\u201370.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2438_CR190","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00624-9","volume":"13","author":"B Farkas","year":"2020","unstructured":"Farkas B, Boldizsar F, Bohonyi N, Farkas N, Marczi S, Kovacs GL, et al. Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS). J Ovarian Res. 2020;13(1):25.","journal-title":"J Ovarian Res"},{"issue":"3","key":"2438_CR191","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s13277-015-4198-0","volume":"37","author":"N Zhan","year":"2016","unstructured":"Zhan N, Dong W-G, Wang J. The clinical significance of vascular endothelial growth factor in malignant ascites. Tumor Biol. 2016;37(3):3719\u201325.","journal-title":"Tumor Biol"},{"issue":"4","key":"2438_CR192","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/00365513.2013.773593","volume":"73","author":"B Liang","year":"2013","unstructured":"Liang B, Guo Z, Li Y, Liu C. Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer. Scand J Clin Lab Invest. 2013;73(4):309\u201314.","journal-title":"Scand J Clin Lab Invest"},{"key":"2438_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215563","author":"C Rogmans","year":"2021","unstructured":"Rogmans C, Kuhlmann JD, Hugendieck G, Link T, Arnold N, Weimer JP, et al. ADAM17-a potential blood-based biomarker for detection of early-stage ovarian cancer. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13215563.","journal-title":"Cancers"},{"issue":"7","key":"2438_CR194","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271630","volume":"17","author":"L Hiepp","year":"2022","unstructured":"Hiepp L, Mayr D, Gartner K, Schmoeckel E, Klauschen F, Burges A, et al. Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas. PLoS One. 2022;17(7):e0271630.","journal-title":"PLoS One"},{"issue":"12","key":"2438_CR195","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051256","volume":"7","author":"H Huang","year":"2012","unstructured":"Huang H, Li Y, Liu J, Zheng M, Feng Y, Hu K, et al. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers. PLoS One. 2012;7(12):e51256-e.","journal-title":"PLoS One"},{"key":"2438_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174291","author":"MJ Carroll","year":"2022","unstructured":"Carroll MJ, Kaipio K, Hynninen J, Carpen O, Hautaniemi S, Page D, et al. A subset of secreted proteins in ascites can predict platinum-free interval in ovarian cancer. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14174291.","journal-title":"Cancers (Basel)"},{"key":"2438_CR197","doi-asserted-by":"publisher","unstructured":"Herzog M, Verdenik I, Kobal B, Cerne K. Higher EpCAM-Positive Extracellular Vesicle Concentration in Ascites Is Associated with Shorter Progression-Free Survival of Patients with Advanced High-Grade Serous Carcinoma. Int J Mol Sci. 2024 Jun 20;25(12):6780. progression-free survival of patients with advanced high-grade serous carcinoma. Int J Mol Sci. 2024;25(12). doi: https:\/\/doi.org\/10.3390\/ijms25126780. PMID: 38928484; PMCID: PMC11204144","DOI":"10.3390\/ijms25126780"},{"key":"2438_CR198","doi-asserted-by":"publisher","unstructured":"Rajtak A, Czerwonka A, Pitter M, Kotarski J, Okla K. Clinical Relevance of Mortalin in Ovarian Cancer Patients. Cells. 2023 Feb 23;12(5):701. doi: https:\/\/doi.org\/10.3390\/cells12050701. PMID: 36899836; PMCID: PMC10000941.","DOI":"10.3390\/cells12050701"},{"issue":"1","key":"2438_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03837-4","volume":"5","author":"S Ueno","year":"2022","unstructured":"Ueno S, Sudo T, Saya H, Sugihara E. Pigment epithelium-derived factor promotes peritoneal dissemination of ovarian cancer through induction of immunosuppressive macrophages. Commun Biol. 2022;5(1):904.","journal-title":"Commun Biol"},{"key":"2438_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101914","volume":"43","author":"B Werner","year":"2024","unstructured":"Werner B, Sjoquist KM, Espinoza D, Yip S, Chang G, Cummins MM, et al. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial. Transl Oncol. 2024;43:101914.","journal-title":"Transl Oncol"},{"issue":"1","key":"2438_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00533-1","volume":"11","author":"M Kfoury","year":"2023","unstructured":"Kfoury M, Hazzaz RE, Sanson C, Durand FB, Michels J, Blameble EC, et al. Circulating tumor DNA from ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients. Biomark Res. 2023;11(1):93.","journal-title":"Biomark Res"},{"key":"2438_CR202","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-60","volume":"6","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wang Y, Li J, Yuan Z, Yuan B, Zhang T, et al. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy. J Hematol Oncol. 2013;6:60.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2438_CR203","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1525-1438.2008.01194.x","volume":"18","author":"RA Tassi","year":"2008","unstructured":"Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, et al. Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18(6):1262\u201371.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"2438_CR204","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007099","volume":"11","author":"Y Wang","year":"2023","unstructured":"Wang Y, He M, Zhang C, Cao K, Zhang G, Yang M, et al. Siglec-9(+) tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer. J Immunother Cancer. 2023;11(9):e007099.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2438_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5611-7","volume":"19","author":"I Matte","year":"2019","unstructured":"Matte I, Garde-Granger P, Bessette P, Pich\u00e9 A. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway. BMC Cancer. 2019;19(1):406.","journal-title":"BMC Cancer"},{"issue":"21","key":"2438_CR206","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215563","volume":"13","author":"C Rogmans","year":"2021","unstructured":"Rogmans C, Kuhlmann JD, Hugendieck G, Link T, Arnold N, Weimer JP, et al. ADAM17-a potential blood-based biomarker for detection of early-stage ovarian cancer. Cancers (Basel). 2021;13(21):5563.","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2438_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174291","volume":"14","author":"MJ Carroll","year":"2022","unstructured":"Carroll MJ, Kaipio K, Hynninen J, Carpen O, Hautaniemi S, Page D, et al. A subset of secreted proteins in ascites can predict platinum-free interval in ovarian cancer. Cancers. 2022;14(17):4291.","journal-title":"Cancers"},{"issue":"7","key":"2438_CR208","doi-asserted-by":"publisher","first-page":"e0271630-e","DOI":"10.1371\/journal.pone.0271630","volume":"17","author":"L Hiepp","year":"2022","unstructured":"Hiepp L, Mayr D, G\u00e4rtner K, Schmoeckel E, Klauschen F, Burges A, et al. Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas. PloS One. 2022;17(7):e0271630-e.","journal-title":"PloS One."},{"issue":"4","key":"2438_CR209","doi-asserted-by":"publisher","first-page":"e1006707","DOI":"10.1371\/journal.pgen.1006707","volume":"13","author":"S Penner-Goeke","year":"2017","unstructured":"Penner-Goeke S, Lichtensztejn Z, Neufeld M, Ali JL, Altman AD, Nachtigal MW, et al. The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples. PLoS Genet. 2017;13(4):e1006707-e.","journal-title":"PLoS Genet"},{"issue":"6","key":"2438_CR210","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/IGC.0000000000000745","volume":"26","author":"RL O\u2019Donnell","year":"2016","unstructured":"O\u2019Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, et al. Advanced ovarian cancer displays functional intratumor heterogeneity that correlates to ex vivo drug sensitivity. Int J Gynecol Cancer. 2016;26(6):1004\u201311.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"2438_CR211","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/PAI.0b013e3181e53e1c","volume":"18","author":"AP Ventura","year":"2010","unstructured":"Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O\u2019Briant K, et al. Activation of the MEK-S6 pathway in high-grade ovarian cancers. Appl Immunohistochem Mol Morphol. 2010;18(6):499\u2013508.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"2438_CR212","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050701","volume":"12","author":"A Rajtak","year":"2023","unstructured":"Rajtak A, Czerwonka A, Pitter M, Kotarski J, Ok\u0142a K. Clinical relevance of mortalin in ovarian cancer patients. Cells. 2023;12(5):701.","journal-title":"Cells"},{"key":"2438_CR213","first-page":"395","volume":"4","author":"RN Eskander","year":"2012","unstructured":"Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012;4:395\u2013404.","journal-title":"Int J Womens Health"},{"issue":"8","key":"2438_CR214","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/1097-0142(196608)19:8<1096::AID-CNCR2820190808>3.0.CO;2-N","volume":"19","author":"IM Ariel","year":"1966","unstructured":"Ariel IM, Oropeza R, Pack GT. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer: results in 267 patients. Cancer. 1966;19(8):1096\u2013102.","journal-title":"Cancer"},{"issue":"12","key":"2438_CR215","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","volume":"14","author":"S Kobold","year":"2009","unstructured":"Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist. 2009;14(12):1242\u201351.","journal-title":"Oncologist"},{"issue":"3","key":"2438_CR216","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","volume":"102","author":"TM Numnum","year":"2006","unstructured":"Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102(3):425\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2438_CR217","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ygyno.2008.04.028","volume":"111","author":"CA Hamilton","year":"2008","unstructured":"Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3):530\u20132.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2438_CR218","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ygyno.2008.07.015","volume":"111","author":"JP Kesterson","year":"2008","unstructured":"Kesterson JP, Mhawech-Fauceglia P, Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol. 2008;111(3):527\u20139.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2438_CR219","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928\u201336.","journal-title":"Lancet Oncol"},{"issue":"17","key":"2438_CR220","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. Oceans: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039\u201345.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2438_CR221","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.ogx.0000452705.82050.e4","volume":"69","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer. Obstet Gynecol Surv. 2014;69(7):402\u20134.","journal-title":"Obstet Gynecol Surv"},{"issue":"2","key":"2438_CR222","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","volume":"13","author":"WH Gotlieb","year":"2012","unstructured":"Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154\u201362.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2438_CR223","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127(9):2209\u201321.","journal-title":"Int J Cancer"},{"issue":"2","key":"2438_CR224","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(11)70394-1","volume":"13","author":"G Becker","year":"2012","unstructured":"Becker G, Blum HE. VEGF trap for the treatment of malignant ascites. Lancet Oncol. 2012;13(2):115\u20136.","journal-title":"Lancet Oncol"},{"key":"2438_CR225","doi-asserted-by":"publisher","unstructured":"Rongbo Lin JX, Rongrui Liu, Ning Li, Guiling Li, Tao Zhang, Jun Zhao, Jiayi Li, Meili Sun, Ke Wang, Hanxiang An, Weijie Zhang, Huiting Xu, Shan Zeng, Mingjun Zhang, Pengfei Zhou, Shaoyi Huang, Xiong Wang. An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial. J Clin Oncol. 2024;42: 16_suppl.\u00a0https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.12060","DOI":"10.1200\/JCO.2024.42.16_suppl.12060"},{"issue":"1","key":"2438_CR226","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123(1):9\u201316.","journal-title":"Br J Cancer"},{"issue":"6","key":"2438_CR227","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1021\/mp200240a","volume":"8","author":"JP Gillet","year":"2011","unstructured":"Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, et al. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm. 2011;8(6):2080\u20138.","journal-title":"Mol Pharm"},{"issue":"7","key":"2438_CR228","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.humpath.2010.10.025","volume":"42","author":"TE Hetland","year":"2011","unstructured":"Hetland TE, Hellesylt E, Florenes VA, Trope C, Davidson B, Kaern J. Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol. 2011;42(7):1019\u201326.","journal-title":"Hum Pathol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02438-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:39:55Z","timestamp":1760456395000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02438-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":228,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2438"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02438-z","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approve of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DLR receives consulting fees from Daiichi Sankyo, Genmab, GSK, Incyclix, Repare, and Immunogen, and speaking fees from Zentalis. The remaining authors declare that they have no affiliation with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}